Literature DB >> 6092675

Structure of the heterogeneous L-S junction region of human cytomegalovirus strain AD169 DNA.

J C Tamashiro, D Filpula, T Friedmann, D H Spector.   

Abstract

The genome of human cytomegalovirus strain AD169 contains a region of heterogeneity located at the junction between the long (L) and short (S) components of the viral DNA. Twelve cloned L-S junction fragments were studied by using the restriction enzymes HaeII and XhoI. The region of heterogeneity was localized within a single HaeII restriction fragment. The enzyme XhoI was used to subdivide this region and revealed the presence of three types of heterogeneity within the junction fragments. Each of the cloned junction fragments contained one of the following fragments: 0.553, 0.95, or 1.35 kilobase pairs (referred to as class I heterogeneity). Class II heterogeneity was defined as the presence of tandem duplications of class I fragments. In addition, a variable number (0 to 5) of a 0.2-kbp fragment (class III heterogeneity) was observed. Mapping of these fragments with partial XhoI digestions revealed that the class I and class III heterogeneous fragments were adjacent. The DNA sequence of the smallest cloned L-S junction fragment was determined and analyzed. This junction fragment contained a single 0.553-kbp XhoI fragment and no copies of the 0.2-kbp fragment. The 0.553-kbp XhoI fragment was similar in structure to the a-sequences of herpes simplex virus types 1 and 2. In addition, a region of homology was found between the a sequences of herpes simplex virus types 1 and 2 and the 0.553-kbp XhoI fragment from the human cytomegalovirus junction.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6092675      PMCID: PMC254556     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Size and complexity of human cytomegalovirus DNA.

Authors:  J M DeMarchi; M L Blankenship; G D Brown; A S Kaplan
Journal:  Virology       Date:  1978-09       Impact factor: 3.616

2.  Structure of the joint region and the termini of the DNA of herpes simplex virus type 1.

Authors:  M J Wagner; W C Summers
Journal:  J Virol       Date:  1978-08       Impact factor: 5.103

3.  Inverted repetitions in the chromosome of herpes simplex virus.

Authors:  P Sheldrick; N Berthelot
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1975

4.  Anatomy of herpes simplex virus DNA. II. Size, composition, and arrangement of inverted terminal repetitions.

Authors:  S Wadsworth; R J Jacob; B Roizman
Journal:  J Virol       Date:  1975-06       Impact factor: 5.103

5.  Human cytomegalovirus DNA. I. Molecular weight and infectivity.

Authors:  J L Geelen; C Walig; P Wertheim; J van der Noordaa
Journal:  J Virol       Date:  1978-06       Impact factor: 5.103

6.  A strategy of DNA sequencing employing computer programs.

Authors:  R Staden
Journal:  Nucleic Acids Res       Date:  1979-06-11       Impact factor: 16.971

7.  A simple method for DNA restriction site mapping.

Authors:  H O Smith; M L Birnstiel
Journal:  Nucleic Acids Res       Date:  1976-09       Impact factor: 16.971

8.  Sequence data handling by computer.

Authors:  R Staden
Journal:  Nucleic Acids Res       Date:  1977-11       Impact factor: 16.971

9.  Human cytomegalovirus genome: partial denaturation map and organization of genome sequences.

Authors:  B A Kilpatrick; E S Huang
Journal:  J Virol       Date:  1977-10       Impact factor: 5.103

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  31 in total

1.  The ends on herpesvirus DNA replicative concatemers contain pac2 cis cleavage/packaging elements and their formation is controlled by terminal cis sequences.

Authors:  M A McVoy; D E Nixon; J K Hur; S P Adler
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Cloning of the full-length rhesus cytomegalovirus genome as an infectious and self-excisable bacterial artificial chromosome for analysis of viral pathogenesis.

Authors:  W L William Chang; Peter A Barry
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  Rapid epidemiologic analysis of cytomegalovirus by using polymerase chain reaction amplification of the L-S junction region.

Authors:  D M Sokol; G J Demmler; G J Buffone
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

4.  A cluster of dispensable genes within the human cytomegalovirus genome short component: IRS1, US1 through US5, and the US6 family.

Authors:  T R Jones; V P Muzithras
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

5.  Sequences within the herpesvirus-conserved pac1 and pac2 motifs are required for cleavage and packaging of the murine cytomegalovirus genome.

Authors:  M A McVoy; D E Nixon; S P Adler; E S Mocarski
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

6.  Circularization and cleavage of guinea pig cytomegalovirus genomes.

Authors:  M A McVoy; D E Nixon; S P Adler
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

7.  Terminal repetitive sequences in herpesvirus saimiri virion DNA.

Authors:  A T Bankier; W Dietrich; R Baer; B G Barrell; F Colbère-Garapin; B Fleckenstein; W Bodemer
Journal:  J Virol       Date:  1985-07       Impact factor: 5.103

8.  Analysis of the major transcripts encoded by the long repeat of human cytomegalovirus strain AD169.

Authors:  S H McDonough; S I Staprans; D H Spector
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

9.  The alpha sequence of the cytomegalovirus genome functions as a cleavage/packaging signal for herpes simplex virus defective genomes.

Authors:  R R Spaete; E S Mocarski
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

10.  Sequences in the human cytomegalovirus 2.7-kilobase RNA promoter which mediate its regulation as an early gene.

Authors:  K M Klucher; D K Rabert; D H Spector
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.